Filter by Lead Doctor (All Doctors) Naveed Wagle, M.D. Title Physician Pembrolizumab and Pemetrexed for Progressive Chordoma NCT ID : NCT06794645 Phase : 2 Location : Saint John's Cancer Institute Naveed Wagle, M.D. CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) NCT ID : NCT03328078 Phase : 1/2 Location : Saint John's Cancer Institute Naveed Wagle, M.D. A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM (RESTORE) NCT ID : NCT03862430 Phase : 2 Location : Saint John's Cancer Institute Naveed Wagle, M.D. A Randomized Controlled Phase 2 Study of the Ketogenic Diet Versus Standard Dietary Guidance for Patients With Newly Diagnosed Glioblastoma in Combination With Standard-of-care Treatment NCT ID : 05708352 Protocol Number : IIT2022-06-HU-DIET2TREAT Phase : 2 Location : Santa Monica, CA Naveed Wagle, M.D. ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION) NCT ID : 05580562 Protocol Number : ONC201-108 Phase : 3 Location : Saint John's Cancer Institute Naveed Wagle, M.D. Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas NCT ID : 04617002 Protocol Number : ONC028 Phase : N/A Location : Santa Monica, CA Naveed Wagle, M.D. Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma NCT ID : 05561374 Protocol Number : OKN-007-OL Phase : 1 Location : Saint John's Cancer Institute Naveed Wagle, M.D.
